Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: Cellectar Biosciences, Inc.
A PHASE1 clinical study on Multiple Myeloma, this trial is completed. The trial is conducted by Cellectar Biosciences, Inc. and has accumulated 13 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE1
Status: Unknown Status → Active Not Recruiting
-
May 2022 — Sep 2022 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
▶ Show 8 earlier versions
-
Jan 2021 — May 2022 [monthly]
Active Not Recruiting PHASE1
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Unknown Status → Active Not Recruiting
-
Apr 2020 — May 2020 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Feb 2019 — Apr 2020 [monthly]
Recruiting PHASE1
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Apr 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cellectar Biosciences, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .